Skip to main content

Letermovir

ADVERTISEMENT
Identification
Molecular formula
C23H11ClF3N3O2
CAS number
917389-32-3
IUPAC name
6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
State
State

At room temperature, Letermovir is a solid.

Melting point (Celsius)
134.50
Melting point (Kelvin)
407.65
Boiling point (Celsius)
450.00
Boiling point (Kelvin)
723.15
General information
Molecular weight
477.80g/mol
Molar mass
477.7980g/mol
Density
1.4900g/cm3
Appearence

Letermovir is typically a white to off-white crystalline powder.

Comment on solubility

Solubility of 6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one

The solubility of chemical compounds is a key characteristic that influences their behavior and application in various fields. In the case of 6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one (C23H11ClF3N3O2), understanding its solubility properties can provide insights into its potential uses and efficacy.

Factors Affecting Solubility

Several factors typically influence the solubility of compounds like this one:

  • Polarity: The presence of chlorine and trifluoromethyl groups can affect the overall polarity of the molecule, impacting how well it dissolves in polar vs. non-polar solvents.
  • Hydrogen Bonding: The benzoxazinone moiety may participate in hydrogen bonding, which can enhance or inhibit solubility in various solvents.
  • Temperature: Like many compounds, solubility may increase with temperature, thereby changing its behavior in solution.

Potential Solubility

While specific solubility data for this compound may not be readily available, it is reasonable to hypothesize:

  • Based on structural features, it may exhibit moderate solubility in organic solvents such as dimethyl sulfoxide (DMSO) or ethanol.
  • Solubility in water is likely to be low due to the hydrophobic character introduced by the cyclopropyl and trifluoromethyl groups.

In summary, the solubility of 6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one plays a crucial role in its usability across different domains, and understanding these characteristics can greatly assist in its practical application.

Interesting facts

Interesting Facts about 6-Chloro-4-(2-Cyclopropylethynyl)-4-(Trifluoromethyl)-1H-3,1-Benzoxazin-2-one

This compound is a fascinating example of modern synthetic chemistry, combining unique structural and functional features that hold potential in various applications. Here are some intriguing insights:

  • Structural Diversity: The presence of both a chloro group and a trifluoromethyl group enhances the compound's electronic properties and reactivity, making it a prime candidate for further derivatization in drug design.
  • Cyclopropyl Moiety: The incorporation of a cyclopropyl group is noteworthy. Cyclopropyl rings can impart strain and unique steric effects, influencing biological activity and leading to compounds with enhanced pharmacological profiles.
  • Benzoxazinone Framework: The benzoxazinone structure is recognized for its role in various bioactive compounds, often associated with anti-tumor and anti-inflammatory activities. This suggests potential therapeutic implications for the synthesized compound.
  • Fluorine’s Influence: The trifluoromethyl group not only affects lipophilicity but also helps in modulating the compound's metabolic stability, an important consideration in drug development.
  • Bioactivity Potential: Compounds with such intricate architectures have been studied for their activity against certain cancer cell lines, highlighting their importance in medicinal chemistry research.

As a result of its complex design, 6-Chloro-4-(2-Cyclopropylethynyl)-4-(Trifluoromethyl)-1H-3,1-Benzoxazin-2-one exemplifies how structural modifications can lead to enhanced functional properties. This compound is not only of academic interest but also poses promising avenues for therapeutic innovations.

Synonyms
Rac-Efavirenz
177530-93-7
L 741211
6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
154635-17-3
rac Efavirenz
6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
Efavirenz Racemic
(Rac)-Efavirenz
rac Efavirenz-d4
6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1H-benzo[d][1,3]oxazin-2(4H)-one
6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
SMR000718784
L-741211
Racemic-Efavirenz
NCGC00159337-02
1246812-58-7
Efavirenz Racemic; ((+/-)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one)
(+/-)-Efavirenz
1261394-62-0
Efavirenz Racemic (20mg)
6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
L741211
MLS001304019
MLS006011825
CHEMBL59507
SCHEMBL464769
DTXSID00861416
HMS2231D09
HMS3373J19
HVB64295
WZB81258
Tox21 111582
BBL010771
HY-10572B
STK582240
STL454184
AKOS005506207
2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-
6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-3-one
NCGC00159337-03
NCGC00159337-06
FC100188
SY009682
VS-02672
CS-0092492
AB00876268-06
(+) 6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl- 1,4-dihydro-2H-3,1-benzoxazin-2-one
(+) 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(+/-) 6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(+/-)6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one
6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-4H-3,1-benzoxazin-2-ol
(S)-6-Chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one